Platelet-derived RGS18 shields circulating tumor cells from NK-mediated immune surveillance by binding to the immune checkpoint HLA-E:KLRD1-NKG2A, according to Liu et al. By blocking inhibitory signaling, immune clearance of CTCs inhibits tumor metastasis in vivo18. The gene discussed is HLA-E; the disease is neoplasm.